oral or injectable semaglutide Effectiveness of versus in Adults with Type 2 Diabetes: Results from a Retrospective Observational Study in Croatia Oral Semaglutide vs Injection Semaglutide

Because they are part of larger health systems, they often have priority access to supply chains

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously a mechanism that sets it apart from existing licensed treatments

This limitation highlights the need for longitudinal studies to evaluate the sustained efficacy of GLP-1RAs and explore strategies to mitigate tolerance, such as dose adjustments or combination therapies

PMID 8365048

What the research shows In the STEP 1 trial, adults taking once-weekly semaglutide 2.4 mg lost an average of about 15% of their body weight over 68 weeks

Always consult a healthcare professional before adjusting your dose